VACSAF
LIVE

Serial Number

79221183

Owner

SISAF Ltd

Attorney

Helen Hill Minsker

Filing Date

Oct 27, 2017

Add to watchlist:

No watchlists yet
View on USPTO

VACSAF Trademark

Serial Number: 79221183 • Registration: 5651894

VACSAF is a trademark filed by SISAF Ltd on October 27, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

SISAF Ltd (10 trademarks)

3 Huxley Road,

Entity Type: 99

Trademark Details

Filing Date

October 27, 2017

Registration Date

January 15, 2019

Published for Opposition

October 30, 2018

Cancellation Date

August 1, 2025

Goods & Services

Chemicals and chemical preparations for use in industry, science and research; Biochemical substances and biochemical preparations for use in industry, science and research, namely, excipients for use in the manufacture of pharmaceutical preparations, cosmetic preparations, nutraceutical preparations, veterinary preparations, dietary supplements, foods and pharmaceutical preparations for topical use; Chemical preparations for pharmaceutical, medical and veterinary research in the nature of reagents and substrates, namely, chemical compounds for use in patterning at nano scale or near nano scale; Silicon for use in industry, science and research; Silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Porous silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Chemical materials, namely, chemical catalysts for carrying and delivery of chemical, biochemical and biological substances for use in industry and not for medical or veterinary use; Silicon for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Nanoparticle materials, namely, silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Silicon nanoparticle materials being silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Porous silicon nanoparticle materials being silicon-based chemical compounds for stabilising enzymes of chemical, biochemical and biological substances for use in industry and for scientific research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for pharmaceutical research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for scientific research in the field of medicine, veterinary and pharmaceutics; Excipient for use in the manufacture of pharmaceutical products, including for the manufacture of vaccines and veterinary preparations

Antiviral pharmaceutical preparations, anti-infective pharmaceutical preparations, anti-inflammatory pharmaceutical preparations, antiseptic pharmaceutical preparations, antibacterial pharmaceutical preparations, antibiotic pharmaceutical preparations, antifungal pharmaceutical preparations, and anti-fibrotic pharmaceutical preparations; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, pulmonary diseases and disorders, immune system related diseases and disorders, hematological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, gastro-intestinal diseases, eye diseases and conditions, heart rhythm disorders, kidney diseases, nephropathic diseases, hematological disorders, diabetes, hypertension, skin disorders, damaged skin and tissue, wrinkles, wounds and allergies, insect bites, dermatological diseases and disorders, HIV, cancer and tumors, bone diseases, arthritis, cardiopulmonary diseases and disorders, infectious diseases, blood disorders, pain, sepsis, alopecia, obesity, cognitive disorders and diseases, neurological disorders, hormonal disorders, disorders of the autoimmune system, metabolic system diseases and disorders, endocrine system diseases and disorders, genitourinary system diseases and disorders; Preparations in the nature of animal feed supplements containing trace elements; Preparations in the nature of human vaccine preparations containing trace elements; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals, nutraceutical and veterinary products; Drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; Chemical, biochemical, biological and pharmaceutical substances for medicinal use being pharmaceutical preparation stabilizers

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 1, 2026 INTR
CANCELLED SECTION 71
Aug 1, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 15, 2024 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
May 17, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 1, 2019 FICS
FINAL DISPOSITION PROCESSED
Apr 30, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 15, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 15, 2019 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 14, 2018 TCCA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 30, 2018 NPUB
PUBLISHED FOR OPPOSITION
Oct 30, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Oct 26, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 10, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 10, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 10, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 18, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 18, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 18, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 18, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 18, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 31, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 31, 2018 CRFA
ASSIGNED TO LIE
Aug 30, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 15, 2018 TROA
REFUSAL PROCESSED BY IB
Mar 9, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 16, 2018 RFCS
REFUSAL PROCESSED BY MPU
Feb 16, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 13, 2018 RFCR
NON-FINAL ACTION WRITTEN
Feb 12, 2018 CNRT
ASSIGNED TO EXAMINER
Feb 6, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 29, 2017 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 25, 2017 NWOS
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Nov 16, 2017 SDRC